Topic: checkpoint inhibitors
Months after raising a $107 million series C, Arcus Biosciences has filed for a $100 million IPO.
Stanford researchers are reporting promising results from mouse trials of a therapy that involves injecting compounds directly into tumors.
Syndax is set to put its cocktail through a phase 1b solid tumor trial ahead of midphase trials to demonstrate its safety and efficacy.
The new agreement clears the Roche subsidiary to test its Tecentriq in combination with Syndax’s entinostat in a subset of breast cancer patients.
Oncolytic viruses used in tandem with other treatments could be key for difficult-to-treat breast and brain cancers.
Two new research insights might help make checkpoint inhibition an effective option for many more lung cancer patients.
Sanofi and Regeneron have touted new topline data for their midstage checkpoint inhibitor in a certain form of skin cancer this morning.
Roche is uncovering data from a Tecentriq trial in bladder cancer patients that could provide clues to countering resistance to checkpoint inhibitors.
Doctors in Paris discovered that when they treated an HIV-infected lung cancer patient with Opdivo, reservoirs of the virus shrunk.
The Parker Institute for Cancer Immunotherapy is sponsoring the trial, which will take place at the MD Anderson Cancer Center.